Physician profile
Anu Sharma
NPI 1891732848
$4,210.21
in general payments reported to CMS, 2019-2025
23 companies · $649 in 2025
The $649 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $295 · 2021: $259 · 2022: $269 · 2023: $1,714 · 2024: $523 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Consulting Fee: $1,400 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.56 |
| Consulting Fee | $1,400.00 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $1,423.84 | 2023-2024 | Idacio |
| Abbvie INC. | $1,238.14 | 2019-2025 | Rinvoq |
| Amgen INC. | $538.29 | 2019-2025 | Enbrel, Otezla, Enbrel |
| Ucb, INC. | $181.99 | 2019-2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $169.86 | 2019-2024 | Simponi Aria, Tremfya, Remicade |
| Astrazeneca Pharmaceuticals Lp | $84.42 | 2022-2025 | Saphnelo |
| Genentech USA, INC. | $70.14 | 2019-2025 | Gazyva, Actemra, Rituxan |
| Pfizer INC. | $69.76 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $69.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $52.47 | 2020-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $44.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $39.65 | 2019 | |
| Mallinckrodt Enterprises LLC | $33.78 | 2019 | |
| Sandoz INC. | $31.73 | 2024 | Hyrimoz |
| Horizon Therapeutics Plc | $23.70 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $21.93 | 2023 | Iovera |
| US Oncology Corporate, INC. | $20.50 | 2023 | |
| Celgene Corporation | $19.24 | 2019 | |
| Avanos Medical | $19.00 | 2021 | |
| Radius Health, INC. | $17.57 | 2023 | Tymlos |
| Genzyme Corporation | $14.64 | 2025 | |
| Novo Nordisk INC | $14.06 | 2019 | |
| Medexus Pharma, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.